MORGAN STANLEY PLC/CALL/ELI LILLY & CO/430/0.01/20.09.24 | Market Closed - Börse Stuttgart 02:43:15 2024-07-12 pm EDT | ||
| 4.81 EUR | +3.44% |
|
| Current month | +5.25% | ||
| 1 month | +17.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.81 | +3.44% |
| 24-07-11 | 4.65 | -2.52% |
| 24-07-10 | 4.77 | +2.14% |
| 24-07-09 | 4.67 | +2.19% |
| 24-07-08 | 4.57 | +0.66% |
Delayed Quote Börse Stuttgart
Last update July 12, 2024 at 02:43 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB4QTK |
| ISIN | DE000MB4QTK9 |
| Date issued | 2023-03-22 |
| Strike | 430 $ |
| Maturity | 2024-09-20 (70 Days) |
| Parity | 100 : 1 |
| Emission price | 0.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.81 € |
|---|---|
| Lowest since issue | 0.225 € |
| Spread | 0.01 € |
| Spread % | 0.21% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Warrants
- Warrant
